MedTrace Logo

Oxidative Stress and Cognitive Dysfunction After COVID-19

NCT07029048 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 45

Last updated 2025-06-25

No results posted yet for this study

Summary

This observational cohort study will investigate the association between oxidative stress biomarkers and post-COVID-19 cognitive impairment. A total of 45 recovered COVID-19 patients aged 30-65 will be enrolled and followed at three intervals: 0-3, 3-6, and 6-12 months post-infection. Cognitive function will be assessed using standardized memory and attention tests, while venous blood samples will be analyzed for nitric oxide, AOPP, NETs, and extracellular nucleic acids. The study aims to identify early predictors of long COVID cognitive sequelae and evaluate biological mechanisms underlying persistent neurocognitive symptoms.

Conditions

  • COVID 19
  • Oxydative Stress
  • Cognitive Impairments

Interventions

OTHER

Standard Post-COVID Rehabilitation Program

This standardized rehabilitation intervention includes a 14-day inpatient course comprising physiotherapy, therapeutic exercises, massage, and respiratory gymnastics. The program is delivered equally to all participants regardless of cognitive status and is intended to promote post-viral recovery in patients recently discharged following COVID-19 pneumonia. No specific cognitive therapy or pharmacological treatment is administered during the rehabilitation period. The intervention is used as background care, not as an experimental variable.

Sponsors & Collaborators

  • Karaganda Medical University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-01
Primary Completion
2023-06-01
Completion
2023-06-01

Countries

  • Kazakhstan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07029048 on ClinicalTrials.gov